Investment will see the German pharmaceutical group build a 1,000 sq m of cleanroom space for formulating and distributing avian vaccines
Render of the three-storey building to boast 1,000 sq m of cleanroom space
Boehringer Ingelheim, the German pharmaceutical group, will invest â‚¬65 million in avian vaccines. The company has laid the first stone of a 5,700 sq m building at its Lyon Porte-des-Alpes (LPA) site in France.
Known as F2IVE (Formulation and Filling of Inactivated Vaccines Extension), this major project will comprise a three-storey building, including 1,000 sq m of cleanroom space mainly for formulating and distributing avian vaccines.
â€śAs poultry consumption continues to rise around the world, there is an increasing demand for avian vaccines. This meant that our LPA production site in Saint-Priest was going to reach a saturation point by 2020. We had to do some forward planning and find additional production capacityâ€ť, explains Erick Lelouche, president of Boehringer Ingelheim Animal Health France.
The new building, which has an environmentally friendly design, will house two formulation lines, a multi-format bottle distribution line and a bag distribution area.
Earthworks for the new high-tech building began in March 2018 with the first batches expected in spring 2020 for a range of avian vaccines destined for the world market, with the exception of the US.
Fifteen months after the acquisition of Merial (a Sanofi company) in January 2017, this new investment will lead to the creation of 42 new jobs, primarily consisting of qualified operations staff (flow and maintenance managers, production technicians).
â€śAn investment such as this confirms the commitment made by Boehringer Ingelheim at the time of the acquisition to put France, and Lyon in particular, at the heart of its growth strategy in the animal health marketâ€ť, commented Lelouche.
Over the past 22 years, more than â‚¬350 million have been invested in the LPA site. This new investment will eventually result in a threefold increase in the siteâ€™s inactivated vaccine production capacity.